AroCell AB (publ) announces today that a research poster submitted by Kiran Kumar J et al entitled ”The AroCell TK 210 ELISA may complement Pro PSA and the Prostate Health Index in differentiating pre-cancerous and cancerous conditions in prostate cancer” was accepted by the AARC for presentation at their annual meeting in April 2017.
The purpose of this study was to compare the AroCell TK 210 ELISA with PSA, free PSA, pro PSA and PHI (prostate health index) in men with pre-cancerous conditions and patients with confirmed prostate cancer.
Serum samples from 94 patients with known PSA values for prostate cancer were collected by the University Medical Centre, Ljubljana. Overall, the AroCell TK 210 ELISA showed significant correlation with PHI (r=032, P=0.0017) and pro PSA (r021 P=0.044) but not with free PSA or PSA.
CEO Jan Stålemark states “We are delighted that this preliminary study demonstrates that serum TK1 assayed with AroCell TK 210 ELISA can differentiate between pre-cancerous conditions and prostate cancer patients with a similar accuracy to that of pro PSA. Further clinical studies will establish the capacity of AroCell TK 210 ELISA to complement pro PSA and PHI in distinguishing between pre-cancerous and prostate cancer, potentially providing another tool in prostate cancer management”.
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 11:45 CET on 24 January 2017.
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.